annabel smith

Medical Oncologist in Adelaide, South Australia.

[Nicolas Cole 🚢👻 @Nicolascole77]

These graphics summarize some of life's hardest lessons.

1/ Distractions fill the space we give them.

[Pashtoon Kasi MD, MS @pashtoonkasi]

📍@ASCO GI23 is now even more special.

I was part of a trial that led to an approval✅ @US_FDA.🙌🏾👏🏾🤗

❓What do you need to know about #HER2🎯& studies in #colorectalcancer?

👇🏾Here’s the money slide. @OncoAlert

From HERACLES to MOUNTAINEER ⛰️.

💡How to sequence? 💭 #CRCSM

[Ishwaria Mohan Subbiah, MD MS FASCO @IshwariaMD]

Worried that discussing #prognosis may harm the patient' emotional wellbeing & relationship w their doc?

This @JCO_ASCO study shows otherwise — Prognostic disclosure was NOT associated w worse sadness, anxiety, or pt-physician relationship ratings #hapc
🌐https://t.co/d8ys1Bzbm3

[Helen OConnell AO @OconnellProf]

@drannabelsmith
Navigating the range and sequence of PC options
@ANZUPtrials and other trial activities alive and well 👋🏼👋🏼👋🏼

[PUNS @ThePunnyWorld]

What's the difference between black
eyed peas and chickpeas?

Black eyed peas can sing us a song while chickpeas can only hummus one

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#WCGIC2022 #HPBCsm
Final results of FIGHT202 ph2 pemigatinib in pretreated CCA with FGFR2 fusions @ArndtVogel
➡️ ORR 37%
➡️ DOR 9 mos
➡️ OS 17.8 mos
🔈 we need to profile CCAs 🧬
- incidence 10-15%
Unfortunately still no path to funding in 🇨🇦 yet…
@myESMO @ESMOWorldGI

[Massimo Di Maio @MassimoDiMaio75]

@oncology_bg Evergreen
https://t.co/F1ggXm0Xuh

[Andrea Cercek @AndreaCercek]

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

[annabel smith @drannabelsmith]

@ChrisKarapetis

[annabel smith @drannabelsmith]

Very happy to share our review of IO in UGI cancers published in BJC this week ‘Immunotherapy use in oesophagogastric cancers—a review of the literature’ | British Journal of Cancer ⁦@BrJCancer⁩ https://t.co/luQ2Xxsh03

[ausyoungoncs @ausyoungoncs]

Applications due the 31/3 for a great opportunity to develop a protocol! @TOGAANZ @AOParsonson @MilitaZaheed @nicolafoneil @JuliaLaiKwon @DKarikios @DrMarkNalder @Mal16354906

[Vivek Subbiah, MD @VivekSubbiah]

➡️ORR
✅FGFR fusions =25.0%
✅FGFR mutations =23.1%
✅partial responses in ➡️cholangiocarcinoma, head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, & non-small cell lung cancer @OncoAlert

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#GU22 @ASCO Abs#491: In Checkmate-274 trial of adjuvant nivolumab in #bladdercancer👉in the CPS ≥ 1 subgroup, median DFS with nivolumab was more than double that with placebo (CPS more relevant than TPS). https://t.co/NCO9WtER5k @MattGalsky @OncoAlert @AndreaNecchi

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#GU22 @ASCO PROpel ph 3 trial met its primary objective: improvement in rPFS for olaparib + abiraterone vs placebo + abiraterone in pts with new mCRPC #prostatecancer (no prior NHT),irrespective of HRR status👇. Weblink👉https://t.co/2kyd4ruRyU @OncoAlert @PCF_Science @urotoday

[NZSOncology @NzsOncology]

New paper released from @myESMO titled, "Female leadership in Oncology" Scatterplot of female proportion between speakers (at congresses) and board members (2019 data). Proud of NZSO's position on the chart!

[Prof. Eva Segelov @profevasegelov]

So, let’s talk about nearManels @ManelWatchAU @ManelWatchUS @ManelWatchNZ @_WomenSpeakers_ @ManelWatchIre @manelwatchpk #MedTwitter What % should be women to save us the token sole female on any panel of 4 or more? Please vote

[Prof Louise Purton @purton_louise]

Finally the L3 outcomes (all level E). It’s a huge loss for women. And collectively the data prove that retention, not recruitment, of women in STEMM research is the biggest issue Australia has. The situation has not changed for over 30 years, despite increased awareness 🤷‍♀️. 6/6

[RACSurgeons @RACSurgeons]

RACS is phasing out the use of gendered titles for surgeons, which can create power and status differences between surgeons and other medical professionals, male and female surgeons, and women who are married and women who are not. Find out more: https://t.co/jYqraY14XD